FGFR1 and central nervous system cancer: A single-centre study of Debio1347 (FGFR1/2/3 inhibitor) in 5 paediatric patients with recurrent or refractory FGFR-altered gliomas demonstrated promising results, inducing partial responses (PR) in two (1 x LGG and 1 x HGG) and stable disease (SD) in two (2 x LGG) of the four evaluable patients [124].